RO7204239

RO7204239 (emugrobart, GYM329) is a Chugai-originated anti-latent myostatin monoclonal antibody that was licensed to Roche, a biologic designed to block the body's natural brake on muscle growth [1]. As of late 2026, this program has effectively collapsed. In March 2026 Roche discontinued development for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD) after the MANOEUVRE Phase 2 FSHD trial failed to show statistically significant benefit over placebo [2]. On September 28, 2026, Roche discontinued the obesity combination program with tirzepatide (GYMINDA, NCT06965413) following an interim analysis that concluded the pre-specified efficacy objectives were unlikely to be met, and returned all rights to Chugai [3][4]. Chugai has stated it will prepare to resume SMA development and consider out-licensing [3]. The scientific thesis - myostatin suppresses muscle growth, so blocking it should rebuild muscle - remains biologically valid. The clinical thesis has now failed three times for this specific antibody across three distinct indications. Meanwhile Scholar Rock's apitegromab (an anti-latent myostatin antibody with similar design) was FDA-approved on September 11, 2026 as ISEMBYLD for SMA on background SMN2-targeted therapy [5], and Regeneron's trevogrumab reported positive Phase 2 COURAGE data in obesity in October 2026 [6]. The class works. This specific molecule did not.

Emugrobart is a novel biologic, never approved anywhere. The program is now effectively dormant at Roche with rights returned to Chugai. MANATEE (NCT05115110), the Phase 2 SMA trial on risdiplam background, was halted when Roche exited muscle-wasting indications in March 2026 [7]. MANOEUVRE (NCT05548556), the Phase 2 FSHD trial, completed at n=48 and did not meet its efficacy objectives, with no statistically significant improvement over placebo on motor function endpoints after 52 weeks of every-four-week dosing [2][8]. GYMINDA (NCT06965413), the n=285 Phase 2 obesity combination with tirzepatide, was discontinued at interim analysis in September 2026 on efficacy futility, with Chugai confirming no new safety signals [3][4]. A Phase 1 insulin sensitivity study (NCT07137585) in T2DM and obesity was active earlier in 2026 but has no independent path forward absent a new sponsor [9]. The near-term inflection has already occurred and the signal was negative. The only remaining optionality is Chugai restarting SMA development or finding an out-licensing partner - neither is scheduled and neither is a near-term binary.

Myostatin is a protein the body makes to tell muscles to stop growing. It works like a thermostat. When muscle mass gets high enough, myostatin signaling tells muscle cells to put the brakes on building more [10]. Humans and animals born with broken myostatin genes develop oversized, hypertrophic muscles. Belgian Blue cattle and the laboratory 'mighty mouse' myostatin knockouts are the textbook examples. The therapeutic logic: if a disease causes muscle to waste or fail to grow properly, as happens in SMA, muscular dystrophies, age-related sarcopenia, or weight loss on GLP-1 drugs, blocking myostatin should let muscle rebuild. Emugrobart specifically targets latent myostatin, the inactive precursor form, rather than mature active myostatin. The latent-selective approach was developed to improve selectivity. Earlier anti-myostatin antibodies that bound more broadly across the TGF-beta family cross-reacted with activin and other related proteins, which caused unwanted signals in prior trials [11]. The biology is well validated by human and animal genetics. What has repeatedly failed in trials is the translation step: making muscle bigger on imaging does not reliably convert into better walking, strength, or weight-loss quality. Apitegromab now provides the first regulatory validation that this translation can work, but only in a specific setting (SMA on background SMN2 therapy) [5]. Emugrobart tried for the same translation and did not achieve it.

MANATEE (NCT05115110) was the SMA trial that originally anchored this node. Phase 2 in participants already treated with risdiplam, Roche's approved SMN2 splicing modifier for SMA (SMN2 is a backup gene that produces reduced levels of survival motor neuron protein, which is deficient in SMA). Part 1 was a safety and dose-finding run-in. Part 2 was a randomized placebo-controlled efficacy phase on top of risdiplam, designed around the Hammersmith Functional Motor Scale (HFMSE), a 0 to 66 motor function scale where higher scores indicate better physical ability [7]. The trial was halted when Roche exited muscle-wasting indications in March 2026. MANOEUVRE (NCT05548556) in FSHD completed at n=48 with a 52-week every-four-week dosing schedule and a quadriceps contractile muscle volume MRI endpoint; the trial did not demonstrate statistically significant benefit over placebo on motor function, and emugrobart was well tolerated with no new safety signals [2][8]. GYMINDA (NCT06965413) at n=285 was the commercially consequential arm. It compared tirzepatide alone against tirzepatide plus emugrobart, with percent body weight change as the primary endpoint [4]. The design directly tested whether blocking myostatin preserves lean mass during GLP-1-driven weight loss. Chugai disclosed on September 28, 2026 that the interim analysis concluded clinically meaningful weight loss was unlikely to be achieved, which triggered the discontinuation [3].

Our model estimates a 17% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 34%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual, larger-than-typical enrollment for this phase, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk has now been realized across all three active indications. The anti-myostatin class has a two-decade history of producing muscle hypertrophy without matching functional gains. Bimagrumab (originally Novartis, now at Lilly after the Versanis acquisition) showed muscle increases in sporadic inclusion body myositis (sIBM, a progressive inflammatory muscle disease with no approved treatments) but missed its Phase 3 primary endpoint on 6-minute walk distance in the RESILIENT trial [12]. Domagrozumab was discontinued in Duchenne muscular dystrophy after Phase 2 failed on timed function tests [13]. Emugrobart has now joined that pattern in FSHD (MANOEUVRE did not meet efficacy objectives) and in obesity (GYMINDA interim futility). The SMA setting could still be more favorable because risdiplam already treats the underlying motor neuron defect, which is the premise on which apitegromab's approval was built - but MANATEE was halted before producing data, so there is no evidence emugrobart would replicate that result. Safety risk has been low across trials. Chugai confirmed emugrobart was well tolerated in GYMINDA with no new safety signals [3], consistent with FSHD safety data. The latent-selective design appears to have delivered on avoiding the activin cross-reactivity that caused more serious signals in earlier programs. The chronic-dosing safety database remains thin because none of the trials ran to a size or duration that would detect rare long-term events. Competitive risk is now decisively negative. Apitegromab is FDA-approved for SMA on background SMN2 therapy [5], occupying the exact niche MANATEE was designed to address. Trevogrumab (Regeneron) reported positive Phase 2 COURAGE data in October 2026, preserving roughly 42.5 percent of lean mass loss on semaglutide with the 75 mg dose, and is advancing to further studies including older adults with obesity-related sarcopenia [6][14]. Bimagrumab is in Lilly's hands post-Versanis acquisition. Commercial risk is effectively a wind-down: there is no immediate commercial path for emugrobart.

This is now a case study in class validation without molecule validation. The anti-latent myostatin mechanism has been proven by apitegromab's September 11, 2026 FDA approval as ISEMBYLD [5] and by trevogrumab's positive Phase 2 COURAGE readout in October 2026 [6]. The class works. Emugrobart specifically did not, across FSHD (MANOEUVRE did not meet efficacy objectives [2]), obesity (GYMINDA stopped at interim futility [3]), and SMA (MANATEE halted before readout [7]). Specific data points still worth tracking: whether Chugai actually restarts an SMA program with emugrobart and, if so, what dosing/background therapy design they choose (the apitegromab precedent is informative); whether an out-licensing deal materializes; and apitegromab's commercial launch trajectory as the first-approved anti-myostatin, since real-world functional outcomes will shape regulatory receptivity for every follower in the class. Roche's 2024 Group sales were CHF 60.5 billion (approximately $68 billion USD at the 2024 average CHF/USD rate of ~1.13), so bankroll was never the gating factor on this program [15]. The strategic read is that Roche concluded the data did not support further investment in any of the three indications, and that conclusion is corroborated by independent trial failures for other molecules in the class in similar settings. Investor takeaway: do not model this node as a near-term binary; model it as either terminated or long-dated optionality under new ownership.

Program effectively discontinued by Roche across all three indications (SMA and FSHD March 2026; obesity September 28, 2026). Rights returned to Chugai, which has signaled intent to prepare an SMA restart or out-license [3].